Report: Pharma Can Resume Testing Drug Efficacy for Neurological and Respiratory Conditions
Source: Pixabay

Report: Pharma Can Resume Testing Drug Efficacy for Neurological and Respiratory Conditions

RespireRx Pharmaceuticals announced last month it was cleared to resume its ampakine CX717 clinical trials to evaluate the drug’s efficacy in several central nervous system and respiratory disorders, including Pompe…

Continue Reading Report: Pharma Can Resume Testing Drug Efficacy for Neurological and Respiratory Conditions